EV-302: Updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV plus P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).

被引：1

作者：

Powles, Thomas

van der Heijden, Michiel Simon

Loriot, Yohann

Bedke, Jens

Valderrama, Begona P.

Iyer, Gopa

Kikuchi, Eiji

Hoffman-Censits, Jeannie

Vulsteke, Christof

Drakaki, Alexandra

Rausch, Steffen

Arafat, Waddah

Park, Se Hoon

Swami, Umang

Li, Jian-Ri

Gorla, Seema Rao

Homet Moreno, Blanca

Yu, Xuesong

Lu, Yi-Tsung

Gupta, Shilpa

机构：

[1] Queen Mary Univ London, St Bartholomews Hosp, Barts Canc Inst, London, England

[2] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands

[3] Univ Paris Saclay, Dept Med Oncol, Gustave Roussy, Villejuif, France

[4] Univ Paris Saclay, Dept Essais Precoces, Villejuif, France

[5] Klinikum Stuttgart, Dept Urol, Stuttgart, Germany

[6] Klinikum Stuttgart, Eva Mayr Stihl Canc Ctr, Stuttgart, Germany

[7] Hosp Univ Virgen del Rocio, Seville, Spain

[8] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol, New York, NY USA

[9] St Marianna Univ, Dept Urol, Sch Med, Kawasaki, Kanagawa, Japan

[10] Johns Hopkins Med Inst, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[11] Maria Middelares Hosp, Dept Med Oncol, Antwerp, Belgium

[12] Univ Calif Los Angeles, Los Angeles, CA USA

[13] Eberhard Karls Univ Tubingen, Dept Urol, Tubingen, Germany

[14] UT Southwestern Med Ctr, Harold C Simmons Comprehens Canc Ctr, Dallas, TX USA

[15] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

[16] Univ Utah, Dept Med, Huntsman Canc Inst, Salt Lake City, UT USA

[17] Taichung Vet Gen Hosp, Dept Surg, Div Urol, Taichung, Taiwan

[18] Astellas Pharma Inc, Northbrook, IL USA

[19] Merck & Co Inc, Rahway, NJ USA

[20] Pfizer Inc, Bothell, WA USA

[21] Cleveland Clin, Cleveland, OH USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 5_SUPPL期

关键词：

D O I：

10.1200/JCO.2025.43.5_suppl.664

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：1

共 50 条

[21] Enfortumab vedotin plus pembrolizumab as a first-line treatment for advanced urothelial carcinoma: a cost-effectiveness analysis from China based on the EV-302 trial
You, Maojin
Zheng, Qiaoyan
He, Ying
FRONTIERS IN PHARMACOLOGY, 2024, 15
[22] Study EV-103: Update on durability results and long term outcome of enfortumab vedotin plus pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC).
Friedlander, Terence W.
Milowsky, Matthew I.
Bilen, Mehmet Asim
Srinivas, Sandy
Mckay, Rana R.
Flaig, Thomas W.
Hoimes, Christopher J.
Balar, Arjun Vasant
Henry, Elizabeth
Petrylak, Daniel P.
Sasse, Carolyn
Kataria, Ritesh S.
Yu, Yao
Carret, Anne-Sophie
Rosenberg, Jonathan E.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[23] Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV103 cohort K.
O'Donnell, Peter H.
Rosenberg, Jonathan E.
Hoimes, Christopher J.
Petrylak, Daniel P.
Milowsky, Matthew I.
Mckay, Rana R.
Srinivas, Sandy
Friedlander, Terence W.
Ramamurthy, Chethan
Bilen, Mehmet Asim
Burgess, Earle F.
Mar, Nataliya
Moon, Helen
Geynisman, Daniel M.
George, Saby
Carret, Anne-Sophie
Yu, Yao
Guseva, Maria
Moreno, Blanca Homet
Flaig, Thomas W.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[24] Quality of Life, Functioning, and Symptoms in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma From EV-301: A Randomized Phase 3 Trial of Enfortumab Vedotin vs Chemotherapy
Gurney, Howard
Mamtani, Ronac
Rosenberg, Jonathan E.
Powles, Thomas
Sonpavde, Guru P.
Loriot, Yohann
Duran, Ignacio
Lee, Jae Lyun
Matsubara, Nobuaki
Vulsteke, Christof
Castellano, Daniel
Sridhar, Srikala S.
Pappot, Helle
Bedke, Jens
van der Heijden, Michiel
Wu Chunzhang
Hepp, Zsolt
McKay, Caroline
Petrylak, Daniel P.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 66 - 67
[25] Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinoma
Rosenberg, J. E.
Powles, T.
Sonpavde, G. P.
Loriot, Y.
Duran, I.
Lee, J. L.
Matsubara, N.
Vulsteke, C.
Castellano, D.
Mamtani, R.
Sridhar, S. S.
Pappot, H.
Gurney, H. P.
Bedke, J.
Van der Heijden, M. S.
Campbell, M.
Wu, C.
Matsangou, M.
Petrylak, D. P.
ANNALS OF ONCOLOGY, 2021, 32 : S710 - S711
[26] COMPARATIVE NARRATIVE REVIEW OF ONCOLOGY VALUE ASSESSMENT FRAMEWORKS: ENFORTUMAB VEDOTIN (EV) FOR TREATMENT OF LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA (LA/MUC)
Ortiz Nunez, A.
Gonzalez Portela
Zozaya, N.
Meco, I
VALUE IN HEALTH, 2023, 26 (12) : S365 - S365
[27] Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC).
Rosenberg, Jonathan E.
Sridhar, Srikala S.
Zhang, Jingsong
Smith, David C.
Ruether, Joseph D.
Flaig, Thomas W.
Baranda, Joaquina Celebre
Lang, Joshua Michael
Plimack, Elizabeth R.
Sangha, Randeep S.
Heath, Elisabeth I.
Merchan, Jaime R.
Quinn, David I.
Srinivas, Sandy
Milowsky, Matthew I.
Wu, Chunzhang
Gartner, Elaina M.
Melhem-Bertrandt, Amal
Petrylak, Daniel Peter
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[28] EV-301: An open-label, randomized phase III study to evaluate enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC)
Petrylak, D. P.
Rosenberg, J.
Duran, I.
Loriot, Y.
Sonpavde, G.
Wu, C.
Gartner, E.
Melhem-Bertrandt, A.
Powles, T.
ANNALS OF ONCOLOGY, 2018, 29
[29] Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma.
Powles, Thomas
Rosenberg, Jonathan E.
Sonpavde, Guru
Loriot, Yohann
Duran, Ignacio
Lee, Jae-Lyun
Matsubara, Nobuaki
Vulsteke, Christof
Wu Chunzhang
Campbell, Mary S.
Matsangou, Maria
Petrylak, Daniel Peter
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[30] EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma
Petrylak, D. P.
Rosenberg, J. E.
Lee, J.
Yonese, J.
Duran, I.
Loriot, Y.
Sonpavde, G.
Wu, C.
Gartner, E. M.
Melhem-Bertrandt, A.
Powles, T.
ANNALS OF ONCOLOGY, 2019, 30

← 1 2 3 4 5 →